MEPOLIZUMAB REDUCES EXACERBATIONS, OCS AND COST AMONG PATIENTS WITH SEVERE ASTHMA AND THE HIGHEST EXPENDITURES PRIOR TO TREATMENT.

MLA

Lugogo, Njira, et al. “Mepolizumab Reduces Exacerbations, Ocs and Cost among Patients with Severe Asthma and the Highest Expenditures Prior to Treatment.” CHEST, vol. 160, no. 4, Oct. 2021, pp. A1811–14. EBSCOhost, https://doi.org/10.1016/j.chest.2021.07.1636.

APA

Lugogo, N., Bogart, M., Corbridge, T., Packnett, E., Wu, J., & Hahn, B. (2021). Mepolizumab Reduces Exacerbations, Ocs and Cost among Patients with Severe Asthma and the Highest Expenditures Prior to Treatment. CHEST, 160(4), A1811–A1814. https://doi.org/10.1016/j.chest.2021.07.1636

Chicago

Lugogo, Njira, Michael Bogart, Tom Corbridge, Elizabeth Packnett, Juan Wu, and Beth Hahn. 2021. “Mepolizumab Reduces Exacerbations, Ocs and Cost among Patients with Severe Asthma and the Highest Expenditures Prior to Treatment.” CHEST 160 (4): A1811–14. doi:10.1016/j.chest.2021.07.1636.